Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | eCF506 |
Synonyms | |
Therapy Description |
eCF506 is a selective Src inhibitor that inhibits Src phosphorylation and Src-Fak complex formation, potentially leads to inhibition of cell proliferation and antitumor activity (PMID: 34417202). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
eCF506 | eCF-506|eCF 506|NXP900|NXP 900|NXP-900 | SRC Inhibitor 31 | eCF506 is a selective Src inhibitor that inhibits Src phosphorylation and Src-Fak complex formation, potentially leads to inhibition of cell proliferation and antitumor activity (PMID: 34417202). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05873686 | Phase I | eCF506 | A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers | Recruiting | USA | GBR | 0 |